BioWorld

Dec. 15, 2005

Amgen Offers To Buy Out Abgenix For $2.2B In Cash

In what could become one of the top acquisitions of 2005, Amgen Inc. offered to acquire Abgenix Inc. for $22.50 a share - or about $2.2 billion in cash. (BioWorld Today) Read More

Zadaxin Phase III Miss Drops SciClone's Stock 40 Percent

Arena's Obesity Drug Yields Positive Results In Phase IIb

Optimer Brings In $34.2M To Advance Anti-Infectives

ActivBiotics, Metaphore Merge With Two Late-Stage Therapies

Human Genome Sciences Spinning Out CoGenesys

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 17, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.